The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves.
LOS ANGELES (GLOBE NEWSWIRE) – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The GotStocks Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves. The latest episode features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations.
To begin the interview, Fruendt provided an introduction to SenesTech® and its business model.
“SenesTech is a biotech and life sciences company. Our mission is to improve public health by managing animal pest populations through fertility control, particularly one of the world’s oldest issues – rodent control,” Fruendt said. “Right now, we have labels for rats and mice, and we attack the problem at its root cause – reproduction. In essence, what we’re doing is rodent birth control. Many cities and other government agencies are trying to control rodent problems by poisoning and killing and trapping and all those things. We’re a little bit different in that respect.”
“I’ll start out with this fact that usually leaves people with their jaws dropping: two rats, in one year, can become 15,000. That is really the basis for our product. You cannot poison, trap or drown rats fast enough without addressing the reproductive rate, and that is really why our product is in the news a lot right now and why we’re getting such success out in the marketplace.”
“SenesTech started as a research company looking at compounds that would mimic menopause. The company came across something that was developed into a product called ContraPest®. It’s a patented technology that really reduces or eliminates fertility in both females and males. It’s proven itself out in the field, and we introduced some different delivery systems in order to be more focused on how rats are in the marketplace, whether they’re in their burrows or they’re roof rats. We have very loyal customers that love the product, so it’s an attractive solution for them.”
Join IBN’s Carmel Fisher and Joel Fruendt, President and CEO of SenesTech Inc., to learn more about the company’s newest offering, Evolve™, a soft bait product offering similar efficacy to ContraPest with a number of competitive advantages.
To hear the episode and subscribe for future podcasts, visit https://podcast.gotstocks.net
The latest installment of The GotStocks Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About SenesTech
SenesTech® is committed to improving the health of the world by humanely managing animal pest populations through fertility control. Its team is made up of experts in fertility control to manage animal pest populations. SenesTech invented ContraPest®, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve™, an EPA-designated minimum risk contraceptive currently offered for rats and mice. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.
For more information, visit the company’s website at www.SenesTech.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
